Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation

A. Megan Cornelison, MS, PA-C, Rima M Saliba, PhD, Sairah Ahmed, MD, Yago Nieto, MD PhD, Qaiser Bashir, MD, Nina Shah, MD, Simrit Parmar, MD, Krina Patel, MD, Chitra Hosing, MD, Uday R. Popat, MD, Elizabeth J. Shpall, MD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2016) 128 (22): 5884.

https://doi.org/10.1182/blood.V128.22.5884.5884

Published: 2016

Journal Articles

Bortezomib With High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid In a Preparative Regimen For Multiple Myeloma: 5-Year Follow Up

A. Megan Cornelison, MS, PA-C, Yvonne Dinh, Manish Sharma, MD, Nina Shah, MD, Qaiser Bashir, MD, Simrit Parmar, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Richard E Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2013) 122 (21): 5547.

https://doi.org/10.1182/blood.V122.21.5547.5547

Published: 2013

Journal Articles

Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),

Elias Jabbour, Hagop M. Kantarjian, Xuemei Wang, MS, Lynne V. Abruzzo, MD, PhD, A Megan Cornelison, Susan O'Brien, MD, Farhad Ravandi, MD, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Jorge E. Cortes, Guillermo Garcia-Manero

Blood (2011) 118 (21): 3802.

https://doi.org/10.1182/blood.V118.21.3802.3802

Published: 2011

Journal Articles

Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2 nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).

Elias Jabbour, MD, Hagop Kantarjian, MD, A. Megan Cornelison, MSPA, Tapan Kadia, MD, Mary-Alma Welch, MMSC, BA, Lynne V. Abruzzo, MD, PhD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 1232.

https://doi.org/10.1182/blood.V116.21.1232.1232

Published: 2010

Journal Articles

Decitabine (DAC) Can Be Safely Reduced After Achievement of Best Response In Patients (pts) with Myelodysplastic Syndrome (MDS)

A. Megan Cornelison, MSPA, Guillermo Garcia Manero, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD, Tapan Kadia, MD, Jorge Cortes, MD, Susan O'Brien, MD, Gautam Borthakur, MD, Mark Brandt, BS, Elias J Jabbour, MD

Blood (2010) 116 (21): 1858.

https://doi.org/10.1182/blood.V116.21.1858.1858

Published: 2010

Journal Articles

Decitabine Is Effective and Safe In Patients with Chronic Myelomonocytic Leukemia

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, A. Megan Cornelison, MSPA, Tapan Kadia, MD, Gautam Borthakur, MD, Jorge E. Cortes, Guillermo Garcia-Manero, MD

Blood (2010) 116 (21): 4032.

https://doi.org/10.1182/blood.V116.21.4032.4032

Published: 2010

Journal Articles

Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy

Elias Jabbour, MD, Hagop Kantarjian, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Jorge E. Cortes, A. Megan Cornelison, MSPA, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD

Blood (2010) 116 (21): 2936.

https://doi.org/10.1182/blood.V116.21.2936.2936

Published: 2010

NARROW

Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation

Bortezomib With High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid In a Preparative Regimen For Multiple Myeloma: 5-Year Follow Up

Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),

Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2 nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).

Decitabine (DAC) Can Be Safely Reduced After Achievement of Best Response In Patients (pts) with Myelodysplastic Syndrome (MDS)

Decitabine Is Effective and Safe In Patients with Chronic Myelomonocytic Leukemia

Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy

Email alerts

ASH Publications

American Society of Hematology

Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation

Bortezomib With High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid In a Preparative Regimen For Multiple Myeloma: 5-Year Follow Up

Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),

Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2 nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).

Decitabine (DAC) Can Be Safely Reduced After Achievement of Best Response In Patients (pts) with Myelodysplastic Syndrome (MDS)

Decitabine Is Effective and Safe In Patients with Chronic Myelomonocytic Leukemia

Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only